|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PDAP1 |
Gene summary for PDAP1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PDAP1 | Gene ID | 11333 |
| Gene name | PDGFA associated protein 1 | |
| Gene Alias | HASPP28 | |
| Cytomap | 7q22.1 | |
| Gene Type | protein-coding | GO ID | GO:0007154 | UniProtAcc | Q13442 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 11333 | PDAP1 | HTA11_2487_2000001011 | Human | Colorectum | SER | 2.04e-03 | 3.32e-01 | -0.1808 |
| 11333 | PDAP1 | HTA11_347_2000001011 | Human | Colorectum | AD | 3.72e-04 | 2.13e-01 | -0.1954 |
| 11333 | PDAP1 | HTA11_3361_2000001011 | Human | Colorectum | AD | 6.93e-03 | 3.87e-01 | -0.1207 |
| 11333 | PDAP1 | HTA11_696_2000001011 | Human | Colorectum | AD | 6.03e-11 | 3.70e-01 | -0.1464 |
| 11333 | PDAP1 | HTA11_1391_2000001011 | Human | Colorectum | AD | 3.12e-08 | 4.71e-01 | -0.059 |
| 11333 | PDAP1 | HTA11_546_2000001011 | Human | Colorectum | AD | 1.45e-03 | 2.83e-01 | -0.0842 |
| 11333 | PDAP1 | HTA11_866_3004761011 | Human | Colorectum | AD | 2.72e-04 | 2.41e-01 | 0.096 |
| 11333 | PDAP1 | HTA11_7696_3000711011 | Human | Colorectum | AD | 1.75e-02 | 2.41e-01 | 0.0674 |
| 11333 | PDAP1 | HTA11_6818_2000001011 | Human | Colorectum | AD | 3.64e-02 | 4.11e-01 | 0.0112 |
| 11333 | PDAP1 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 1.10e-05 | 2.89e-01 | 0.294 |
| 11333 | PDAP1 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 7.09e-14 | 8.16e-01 | 0.281 |
| 11333 | PDAP1 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 5.90e-12 | 4.30e-01 | 0.3859 |
| 11333 | PDAP1 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 4.49e-11 | 3.78e-01 | 0.3005 |
| 11333 | PDAP1 | AEH-subject1 | Human | Endometrium | AEH | 4.84e-17 | -3.67e-01 | -0.3059 |
| 11333 | PDAP1 | AEH-subject2 | Human | Endometrium | AEH | 4.72e-08 | -2.71e-01 | -0.2525 |
| 11333 | PDAP1 | AEH-subject3 | Human | Endometrium | AEH | 9.87e-16 | -3.48e-01 | -0.2576 |
| 11333 | PDAP1 | AEH-subject4 | Human | Endometrium | AEH | 4.16e-09 | -3.54e-01 | -0.2657 |
| 11333 | PDAP1 | AEH-subject5 | Human | Endometrium | AEH | 2.72e-11 | -3.80e-01 | -0.2953 |
| 11333 | PDAP1 | EEC-subject1 | Human | Endometrium | EEC | 4.16e-20 | -3.81e-01 | -0.2682 |
| 11333 | PDAP1 | EEC-subject2 | Human | Endometrium | EEC | 1.76e-10 | -3.15e-01 | -0.2607 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PDAP1 | SNV | Missense_Mutation | novel | c.384N>G | p.His128Gln | p.H128Q | Q13442 | protein_coding | deleterious(0.03) | benign(0.224) | TCGA-A8-A09A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
| PDAP1 | SNV | Missense_Mutation | c.335N>A | p.Arg112Gln | p.R112Q | Q13442 | protein_coding | deleterious(0.04) | probably_damaging(0.936) | TCGA-B6-A0I5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| PDAP1 | SNV | Missense_Mutation | c.88N>A | p.Glu30Lys | p.E30K | Q13442 | protein_coding | tolerated(0.06) | benign(0.157) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD | |
| PDAP1 | SNV | Missense_Mutation | novel | c.340G>A | p.Glu114Lys | p.E114K | Q13442 | protein_coding | deleterious(0.01) | possibly_damaging(0.908) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| PDAP1 | SNV | Missense_Mutation | c.106G>A | p.Glu36Lys | p.E36K | Q13442 | protein_coding | tolerated(0.42) | benign(0.292) | TCGA-IR-A3LA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| PDAP1 | SNV | Missense_Mutation | c.367N>T | p.Arg123Cys | p.R123C | Q13442 | protein_coding | deleterious(0.03) | probably_damaging(0.94) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| PDAP1 | SNV | Missense_Mutation | c.220N>T | p.Arg74Cys | p.R74C | Q13442 | protein_coding | tolerated(0.06) | benign(0) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
| PDAP1 | SNV | Missense_Mutation | novel | c.398N>T | p.Thr133Ile | p.T133I | Q13442 | protein_coding | deleterious(0) | probably_damaging(0.977) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| PDAP1 | SNV | Missense_Mutation | novel | c.21N>T | p.Lys7Asn | p.K7N | Q13442 | protein_coding | tolerated(0.34) | probably_damaging(0.981) | TCGA-AX-A1C5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | SD |
| PDAP1 | SNV | Missense_Mutation | c.389C>T | p.Ala130Val | p.A130V | Q13442 | protein_coding | deleterious(0.02) | benign(0.163) | TCGA-D1-A176-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |